Differences between Dabotan and Pemetinib

In the field of targeted cancer drugs, many patients are easily confused by the scientific, generic and trade names of the drugs. The relationship between pemigatinib and dalbertam is a typical case. In fact, the two are not two different drugs, but the embodiment of the same targeted drug under different naming systems. Pemetinib is its international common name and the most common name in academic research and international communication. Dabotan is its registered trade name in the Chinese market and is commonly found in domestic hospital pharmacies, prescription orders or medical insurance-related information. In other words, the "Dabotan" that patients see when receiving a doctor's prescription actually corresponds to the drug containing pemetinib.

In terms of drug ingredients, indications, dosage specifications, and clinical effects, Dabotan and Pemetinib are completely identical, and their differences are limited to their naming differences. This situation is common among many imported targeted drugs. For example, after a common name commonly used in the world enters the Chinese market, it will usually get a concise and easy-to-remember trade name so that patients and doctors can use it in daily communication. Therefore, if patients come across different names for dalbertan and pemetinib when checking information or purchasing drugs, they do not need to worry that they are mixing the two drugs. In essence, they are the same.

It needs to be emphasized that despite the different names, the treatment process must be carried out under the professional guidance of a doctor. Patients should not change medicines on their own or purchase them across channels simply based on differences in drug names. For cholangiocarcinoma (CCA) patients who have been diagnosed as suitable for the use of FGFR inhibitors, whether labeled as "pemetinib" or "dalbertam", they should strictly follow the doctor's medication regimen and monitoring requirements to ensure the effectiveness and safety of the treatment. As the market's acceptance of targeted drugs increases, a correct understanding of drug naming differences can help patients reduce their doubts and complete standardized treatment with greater peace of mind.

Reference materials:https://go.drugbank.com/drugs/DB15102